Abstract
HER2-positive breast cancer is one of the most common types of female breast cancer around the world. This review summarizes information and results of HER2 -positive breast cancer trials and compares their results with the standards in Bosnia and Herzegovina. It is done based on a literature search on PubMed and Google Scholar. This review analyzed trastuzumab as a golden treatment standard for HER2 -positive cancer treatments. Trastuzumab is a monoclonal anti-human epidermal growth factor receptor antibody and besides its effect in the treatment of breast cancer, suggests the treatment with trastuzumab within 1 year. Bosnia and Herzegovina have also accepted standards and guidelines for the treatment of HER2 -positive breast cancer and they are in step with the latest achievements worldwide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
